Integra LifeSciences Holdings
$ 13.57
0.59%
04 Dec - close price
- Market Cap 1,057,249,000 USD
- Current Price $ 13.57
- High / Low $ 13.75 / 13.32
- Stock P/E N/A
- Book Value 13.33
- EPS -6.48
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE -0.39 %
- 52 Week High 27.13
- 52 Week Low 10.87
About
Integra LifeSciences Holdings Corporation is a prominent global medical technology firm that specializes in the development and manufacture of innovative surgical implants and medical instruments for a range of applications, including neurosurgery, limb reconstruction, orthopedics, and general surgery. Based in Princeton, New Jersey, Integra is dedicated to improving patient outcomes through cutting-edge products that harness proprietary technologies and advanced research capabilities. With a strategic focus on addressing unmet medical needs, the company is well-positioned to capitalize on growth opportunities within the dynamic healthcare industry.
Analyst Target Price
$15.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-07-31 | 2025-05-05 | 2025-02-26 | 2024-11-04 | 2024-07-29 | 2024-05-06 | 2024-02-28 | 2023-10-25 | 2023-07-26 | 2023-04-26 | 2023-02-22 |
| Reported EPS | 0.54 | 0.45 | -0.3308 | 0.97 | 0.41 | 0.63 | 0.55 | 0.89 | 0.76 | 0.71 | 0.74 | 0.94 |
| Estimated EPS | 0.43 | 0.44 | 0.4311 | 0.8554 | 0.39 | 0.62 | 0.55 | 0.9 | 0.78 | 0.57 | 0.74 | 0.9 |
| Surprise | 0.11 | 0.01 | -0.7619 | 0.1146 | 0.02 | 0.01 | 0 | -0.01 | -0.02 | 0.14 | 0 | 0.04 |
| Surprise Percentage | 25.5814% | 2.2727% | -176.7339% | 13.3972% | 5.1282% | 1.6129% | 0% | -1.1111% | -2.5641% | 24.5614% | 0% | 4.4444% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.8101 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $6.37 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IART
2025-11-01 08:17:00
Integra LifeSciences Holdings Corporation reported Q3 2025 earnings, beating EPS expectations with $0.54 but missing revenue guidance due to supply interruptions. The company discussed progress on its Compliance Master Plan, operational excellence, and reintroduction of PriMatrix and Durepair, while also providing updated full-year 2025 financial guidance. Executives addressed analyst questions regarding Q4 guidance, 2026 growth prospects, private label business challenges, MediHoney remediation, and the strategic portfolio prioritization.
2025-10-15 12:30:00
Integra LifeSciences (Nasdaq: IART) will release its third-quarter 2025 financial results on Thursday, October 30, 2025, before the market opens. Following the release, the company will host a conference call at 8:30 a.m. ET, and a live webcast will be available on its Investors website. Investors can register to receive dial-in details and an individual PIN for the conference call, with a replay also available on the website.
2025-10-15 12:30:00
Integra LifeSciences announced it will host a conference call on October 30, 2025, to discuss its third quarter 2025 financial results. The call will be accessible via a live webcast on the Investors section of the company's website. Integra LifeSciences is a medical technology company focused on restoring patients' lives through surgical, neurologic, and regenerative care.
2025-10-12 07:11:43
Wealth Enhancement Advisory Services LLC recently increased its stake in Integra LifeSciences Holdings Corporation (IART) by purchasing an additional 1,927 shares. Several other institutional investors also adjusted their holdings in IART this quarter. The article notes a recent 5.8% drop in Integra LifeSciences' stock and provides a company profile outlining its product offerings.
2025-06-22 10:00:00
Pomerantz LLP is investigating potential securities fraud claims against Integra LifeSciences Holdings Corporation (IART) on behalf of its investors. This investigation follows Integra's Q1 2025 financial results, which reported significantly missed earnings and revenue guidance, leading to a substantial drop in its stock price. Investors are encouraged to contact the law firm for more information regarding joining a potential class action.
2025-06-09 06:42:00
Integra LifeSciences announced an amendment to its credit agreement, adjusting the company's leverage ratio effective June 6, 2025. This amendment, which modifies the maximum permitted consolidated total leverage ratio and introduces a Covenant Relief Period, aims to manage financial obligations while maintaining strategic flexibility. The company also reported Q1 2025 earnings which missed forecasts, leading JMP analysts to reduce their price target to $25.
